A cohort of 439 haematopoietic SCT recipients was analysed to determine the incidence of Gram-positive coccal bacteraemia and thromboembolic events associated with the use of central venous catheters (CVCs) and to determine risk factors for these complications. The incidences of persistent coagulase-negative staphylococcal (CoNS) bacteraemia, symptomatic thrombosis and thrombophlebitis were 25%, 9.6% and 6.6%, respectively. Duration of neutropenia (in days, odds ratio (OR) 1.02; P ¼ 0.04) and leftsided placement of the CVCs (OR 1.73; P ¼ 0.03) were independent risk factors for the occurrence of persistent CoNS bacteraemia, whereas the use of less mucotoxic conditioning regimens was associated with a lower risk (high-dose melphalan (HDM)/BEAM vs other regimens, OR 0.24; Po0.001). Use of TBI, persistent CoNS bacteraemia and tip colonisation were all significantly associated with an increased risk of symptomatic thrombosis (OR 6.03, 3.36 and 2.80, respectively; Pp0.02). The risk factors found in this cohort of SCT recipients differed from those found in the general cancer population, showing an important role for persisting bacteraemia in the pathogenesis of CVC-associated thrombosis. Therefore, we constructed a new algorithm in order to improve catheter management and prevent these CVC-related complications.
INTRODUCTION
Central venous catheters (CVCs) are widely used for managing patients receiving intensive chemotherapy to prepare them for an autologous or allo-SCT. 1 The use of CVCs is not without complications, with some being related to the insertion procedure (for example, pneumothorax) and others (for example, infection and thrombosis) occurring later. The CVC infection mostly involves coagulase-negative staphylococci (CoNS) that originate from the resident commensal flora of skin and gut, and can occur through either an exogenous route (for instance, migration from the skin along the catheter tract or via catheter hub) or an endogenous route as a result of haematogenous seeding from a distant infection site or disrupted mucosal barriers of the oral cavity and gastrointestinal tract. 2, 3 The pathogenesis of CVC-related thrombosis is complex and is thought to result from activation of coagulation pathways by the foreign material in the bloodstream with formation of a thrombin sheath covering the CVC, the occurrence of vascular endothelial damage and endothelial cell activation by disturbed haemodynamics. 4 Infection can also stimulate thrombus formation by aggravating coagulation, but the presence of a thrombus mass or thrombin sheath around the CVC also increases the risk for microbial colonisation and bacteraemia. 5 The CVC-related thrombosis can result in serious complications, including pulmonary embolism and, when infected, it increases the risk of endocarditis and septic embolisms considerably. 6, 7 We employ a conservative approach towards the treatment of a single episode of bacteraemia due to CoNS and neither routinely employ antibiotics nor remove the CVC. This emanates from our observation that early-onset CoNS bacteraemia results from endogenous spread of the staphylococci from mucosal barrier injury to the oral cavity or gut and does not involve a primary infection of the device. 8, 9 However, persistent CoNS bacteraemia increases the probability of an infection of the CVC and predisposes to device-related thrombosis of the subclavian vein. However, we wished to determine whether or not this hypothesis was justified and hence undertook a retrospective analysis to investigate the risk factors for persistent CoNS bacteraemia and thrombosis, define their relationship to each other and generate a CVC management algorithm based on our findings.
MATERIALS AND METHODS

Study population
BEAM for an autologous SCT; group 2: those who had been given a myeloablative conditioning regimen consisting of CY together with either TBI or BU with or without idarubicin for an allo-SCT; and group 3: those who had been given a nonmyeloablative conditioning regimen consisting mainly of CY together with fludarabine for an allo-SCT. 10 Patients who had received a graft from an unrelated donor had also received antithymocyte globulin.
Supportive care
Patients did not receive haematopoietic growth factors or prophylactic anticoagulants. Antimicrobial prophylaxis consisted of 500 mg ciprofloxacin and 500 mg valaciclovir, both given twice daily. In case of fever during neutropenia, empirical therapy was started with 2000 mg ceftazidime given three times daily intravenously. A single episode of CoNS bacteraemia was not a ground for modifying empirical therapy by adding a glycopeptide to the antimicrobial regimen.
CVC procedure, management and complications All patients had been managed using a nontunnelled, three or four lumen, uncuffed, 8.5 French, polyurethane catheter that was not coated with any antibiotics (Arrow International Inc., USA). CVCs had been inserted by trained personnel, namely, haematologists, physician assistants and nurse specialists. Catheter passports had also been filled out by a nurse during insertion to collect data regarding the CVC procedure. After CVC placement, the proper positioning and absence of pneumothorax had been confirmed by a chest X-ray. Maximal sterile barrier precautions were used during all insertions following Centers for Disease Control and Prevention (CDC) guidelines. 11 Local CVC management was achieved by using chlorhexidine 0.5%/alcohol 75% for disinfection. 11, 12 Antibiotic locks were not used at any time and glycopeptides were only given when clinically indicated.
Blood (10 mL) had been routinely drawn for aerobic culture each Monday and Thursday from each lumen of the CVC. At the onset of fever, 40 mL of peripheral blood had been obtained for culture together with 10 mL from each lumen of the catheter. A blood culture was considered positive if one or more bottles yielded a microorganism, except for CoNS, for which two separate positive blood cultures, drawn at the same time, yielding the same strain were required. 13 Persistent bacteraemia was defined as two or more consecutive episodes of bacteraemia, at least 24 h apart, involving the same bacterial species.
In case of CVC symptoms and signs of thrombosis, an ultrasonography of the upper extremity was performed. In case of a negative ultrasonography and high clinical suspicion of thrombosis, a venography was ordered. Symptomatic thrombosis was defined as a thrombus seen on imaging accompanied by signs and symptoms of upper extremity thrombosis. Septic thrombophlebitis was defined as symptomatic thrombosis accompanied by persistent CoNS. 14 
Statistical analysis
We employed descriptive statistics for patient, SCT procedure and CVC characteristics. Only data on the first CVC episode during SCT were included in the analysis. Data were expressed as frequencies, mean values with s.d. or median values with the range. Differences in median duration of neutropenia and CVC duration were evaluated using Mann-Whitney Utests. Incidences of CoNS bacteraemia, persistent bacteraemia, symptomatic thrombosis and thrombophlebitis were calculated as the proportion of patients experiencing these complications as well as the rate per 1000 CVC-days.
The first episode of bacteraemia due to Gram-positive bacteria that occurred while the CVC was in place was recorded for each patient. Potential risk factors for the occurrence of persistent CoNS bacteraemia and thrombosis were evaluated by means of logistic regression. Potential risk factors were univariately tested with the Wald w 2 test. Those with a P-value of o0.20 were included in the multivariate analysis. The final multivariate model was selected through a backward selection procedure with Po0.05. Confounders that were considered clinically relevant were included in the selection procedure. Crude and adjusted odds ratios (ORs) with 95% confidence interval were presented. In addition, in each model, the ability to discriminate between patients with and without the complication at issue was quantified by the C-index. The association between two dichotomous variables was evaluated with the w 2 test. All statistical analyses were carried out in SAS 9.2 (Cary, NC, USA).
RESULTS
Patient characteristics
We initially reviewed 506 consecutive SCT recipients. A total of 67 patients were excluded from the analysis because of incomplete follow-up due to transfer to another hospital (n ¼ 36), death within the first week of SCT (n ¼ 7), multiple SCTs (n ¼ 20) and lack of surveillance blood cultures (n ¼ 4). The final cohort therefore consisted of 439 patients, of whom 245 (56%) had received an auto-SCT and the remaining 194 (44%) an allo-SCT. The characteristics of these patients and the SCT and CVC procedures are depicted in Table 1 . The CVCs of the 439 patients contributed to a total of 8273 catheter-days. Three-quarters of the CVCs had Conditioning regimen In two other patients, thrombophlebitis was confirmed by positron emission tomography/computed tomography in which septic pulmonary emboli were detected ( Figure 2 ). 15 No deaths were attributed to the CVC-related complications.
As expected, the occurrence of persistent CoNS bacteraemia and/ or thrombosis resulted in early removal of the CVC, and hence an overall shorter median time of the CVC remaining in situ (16 vs 19 days, Po0.0001).
Risk factors for symptomatic thrombosis. In univariate analysis gender, conditioning type, use of TBI, duration of neutropenia, stem cell source, CVC side, occurrence of persistent bacteraemia and CVC tip culture were all associated (Po0.20) with the occurrence of symptomatic thrombosis (Table 2) . In multivariate analysis, only the use of TBI, occurrence of persistent CoNS bacteraemia and a positive CVC tip culture were significantly associated with increased risk. The C-index of the multivariate 
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A Richters et al model was 0.868, indicating that discriminative ability for the occurrence of symptomatic thrombosis by these factors was high. The occurrence of the persisting bacteraemia and symptomatic thrombosis were significantly correlated (w 2 , Po0.0001). Patients who experienced a persistent CoNS bacteraemia developed a symptomatic thrombosis in 29 (26.4%) of 110 cases, opposed to only 13 (4.0%) of the 329 patients who did not (OR 8.70, 95% confidence interval 4.33-17.49, Po0.01). Hence, the negative predictive value of persistent CoNS bacteraemia for the occurrence of symptomatic thrombosis was high (that is, 96%), whereas the positive predictive value was low (that is, 26.5%).
DISCUSSION
We identified several risk factors for persistent CoNS bacteraemia and thrombosis. Persistent CoNS bacteraemia was significantly related to the duration of neutropenia, the conditioning regimen and a left-sided placement of the CVC. Persistence of bacteraemia requires a source of infection and inadequate eradication of the microorganism. This probably explains neutropenia being a risk factor, although residing macrophages and dendritic cells might sometimes be sufficient to eradicate these indolent opportunistic pathogens. This might also explain the fact that 40% of bacteraemias resolved without the use of additional antibiotic therapy. The CVC device itself is usually presumed to be the source of bacteraemia, whereas the mucosal barrier may well be the origin, as the conditioning regimen proved to be an independent and the strongest risk factor associated with persistent bacteraemia. The more myelotoxic regimens are also the most mucotoxic and these resulted in a fourfold increased risk. This suggests that, apart from neutropenia, persistent bacteraemia might well have been directly related to the mucotoxic effects of the conditioning regimen. Moreover, the staphylococci involved may well have originated from the gut as these are usually resistant to the quinolones used for prophylaxis and may overgrow on the gut surfaces left vacant by the microbiota that have been suppressed by the antibiotic. This suggestion is supported by the fact that most of the CoNS bacteraemias occurred 10-14 days after CVC insertion as did the occurrence of OVS bacteraemia, which is known to originate from oral and intestinal mucosal barriers at the peak of intestinal damage. 10 In addition, Costa et al. 8 have shown that most CoNS that were cultured from the blood of SCT recipients were more similar to those recovered from the mucosal surfaces than those from the skin. Although the mucosal barriers might well be the initial source of infection, the question remains of whether persistent bacteraemia results from continuing haematogenous seeding from the mucosa, a secondary infection of the CVC or, indeed, an ongoing primary CVC infection. Importantly, CVC insertion and care measures were implemented according to best practice, and hence colonisation and infection of the CVC via the insertion site by the skin flora was less likely.
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The reason a left-sided placement increased the risk might be related to differences in anatomy and disturbed blood flow. 1 However, it might also be simply a consequence of our preference for a right-sided placement of the CVC over a left-sided placement, as the latter is only chosen when problems arose during the procedure or had occurred in the past (for example, earlier thrombosis). Using standardised CVC procedures in intensive care units has shown that the CVC site of insertion is unimportant, but the setting is not comparable to the haematology wards as few patients in the intensive care units suffer from mucositis and neutropenia induced by cytotoxic therapy. 16 The incidence of catheter-associated thrombosis was relatively high (9.5%), and is in the same range as found in prospective studies and retrospective studies of SCT recipients. [17] [18] [19] [20] However, lower incidences have also been reported, although the use of prophylactic anticoagulants for CVC thrombosis might have influenced these results. [21] [22] [23] We found the use of TBI, occurrence of persistent CoNS bacteraemia and a positive catheter-tip culture-an indication of catheter colonisation-as the strongest risk factors for CVC-associated thrombosis. The use of TBI has seldom been noted as a risk factor for venous thrombosis, but has a pathophysiological basis as TBI is known to induce damage to the vascular endothelium, which is a known risk factor for thrombosis. 24, 25 CVC-related infection is a known risk factor for CVCassociated thrombosis, but it has not been consistently reported in cohort analyses among patients with cancer, although it seems to play an important role in haematology patients and especially in those receiving a SCT. 1 The use of more myelotoxic and mucotoxic regimens to prepare for an SCT exposes patients to more tissue damage, including mucosal and endothelial damage, a higher incidence of bacteraemia, and thus a higher risk for thrombosis. Perturbation of endothelial integrity and function resulting from infection and the presence of intravascular foreign material and the procoagulant effect of infection contribute to enhanced coagulation and thrombus formation culminating in thrombophlebitis. As the definition of CVC-related infection is neither consistent nor easy to employ in clinical practice, thrombotic risk in SCT patients could be better established by monitoring for persistent positive blood cultures. This also obviates contentious discussions on the primary infection sources that are impossible to settle and only tend to confuse rather than clarify decision making.
We did not explore some risk factors for CVC-related thrombosis reported in a large meta-analysis, namely, catheter type, insertion site and catheter-tip position, as the CVCs we employed were of the same type, centrally inserted, and the tip position confirmed by imaging to ensure proper positioning. 26 Nor did we find support for left-sided insertion site and hereditary thrombophilia being risk factors for CVC-associated thrombosis as reported by Tesselaar et al. 19 Hereditary thrombophilia has not been assessed routinely in our patients, and the impact of the CVC insertion site was probably overshadowed in the multivariate analysis by the presence of persistent CoNS bacteraemia as these two variables were highly associated with one another.
In case of suspected deep venous thrombosis or persistent CoNS bacteraemia, the presence of thrombosis should be investigated by ultrasonography, although this diagnostic approach was not very effective in our cohort as we saw a false-negative rate of 47.2%. 27 Venography seemed more appropriate for establishing the diagnosis and may be more useful in haematology patients, although this approach has the disadvantage of detecting clinically irrelevant nonobstructive venous thrombi. In case of suspected thrombophlebitis, positron emission tomography/computed tomography is a more attractive approach as it offers the possibility of detecting septic embolisms, although this requires more research. 15 Nevertheless, others have used ultrasonography successfully for the early detection of thrombophlebitis in selected groups of patients with CVC-related bacteraemia, thereby reducing complications and mortality. 6 As a retrospective analysis, this study has a number of limitations. First, there were missing data in some patients, mainly considering the CVC placement procedure, including number of insertion attempts and insertion time, and hence risk factors might Figure 3 . Algorithm for the management of CVC-related complications. This algorithm depicts our approach to managing CVCs used to manage SCT. Immediately after insertion, blood was obtained from culture every Monday and Thursday. When persistent bacteraemia due to CoNS is established, the question is asked of whether the catheter is still needed or not. If not, the catheter is removed. However, if the catheter is to be retained, the patient is examined for signs or symptoms of thrombosis and, if detected, treatment with teicoplanin is started, provided the CoNS isolate is susceptible. Otherwise the catheter is removed, blood cultures are obtained and appropriate antibiotic treatment is given until the infection is eradicated.
have been missed. Second, the diagnosis of thrombosis depended upon clinical suspicion, as there was no active radiographic surveillance. Therefore, the incidence of thrombosis recorded during our study might actually be an underestimate. Nevertheless, these results reflect usual practice and the clinical significance of asymptomatic catheter-related thrombi remains unknown. The study is, however, very different in one respect, namely, by obtaining blood for culture twice a week from catheter insertion onwards we were able to detect CoNS bacteraemia before there were any signs of fever or infection and 10 days before thrombosis was diagnosed. The incidence of bacteraemia and symptomatic thrombosis we found was similar to that reported in studies on CVC complications of SCT recipients, even though we restricted antibiotic use and used no anticoagulants as prophylaxis. 28, 29 Moreover, we experienced no mortality related to the occurrence of thrombosis and thrombophlebitis. Nevertheless, thrombosis incidence was relatively high and morbidity related to CVC complications was still substantial, and hence there is clearly room for improvement. As persistent CoNS bacteraemia was a strong predictor for thrombosis, the early detection of persistent bacteraemia would likely point to an increased risk for thrombosis sufficiently early to institute appropriate interventions. Consequently, we have modified our clinical CVC care protocol to manage these complications ( Figure 3) . The same restrictions towards the use of glycopeptides is maintained that seems appropriate if costs, toxicity and antibiotic resistance are to be minimised. The starting point is the strong association between persistent CoNS bacteraemia and subsequent complications. Hence, establishing persistent bacteraemia is crucial requiring further blood culture within 2 to 3 days of detecting. In case of persistent CoNS bacteraemia, the CVC should be removed unless there are cogent reasons to retain it. Should this be the case, then thrombosis should be excluded by venography, appropriate antibiotics should be started and a strict follow-up plan executed in order to monitor for CVC complications.
